Intracoronary versus intravenous abciximab administration in patients with ST-elevation myocardial infarction undergoing thrombus aspiration during primary percutaneous coronary intervention-Effects on soluble CD40 ligand concentrations

Atherosclerosis

Volumn 206, Issue 2, 2009, Pages 523-527

  Dominguez Rodriguez, Alberto ^a   Abreu Gonzalez, Pedro ^b   Avanzas, Pablo ^c   Bosa Ojeda, Francisco ^a   Samimi Fard, Sima ^a   Marrero Rodriguez, Francisco ^a   Kaski, Juan Carlos ^d  

^a HOSPITAL UNIVERSITARIO DE CANARIAS   (Spain)

^b UNIVERSIDAD DE LA LAGUNA   (Spain)

^c Hospital Central Asturias   (Spain)

^d ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Abciximab; Intracoronary; Percutaneous coronary intervention; Soluble CD40 ligand; ST elevation myocardial infarction

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CD40 LIGAND; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN;

AGED; ANGIOCARDIOGRAPHY; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLEEDING; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG WITHDRAWAL; EPISTAXIS; FEMALE; HEART INFARCTION; HUMAN; INTRACORONARY INFUSION; LOADING DRUG DOSE; MALE; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION; THROMBUS ASPIRATION;

AGED; AGED, 80 AND OVER; ANGIOPLASTY, BALLOON, CORONARY; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; CD40 LIGAND; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRALESIONAL; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; THROMBOSIS; TREATMENT OUTCOME;

EID: 70349417896     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2009.03.011     Document Type: Article

References (36)

1. Davies M.J., and Thomas A. Thrombosis and acute coronary-artery lesions in sudden cardiac ischemia death. N Engl J Med 310 (1984) 1137-1140
2. Silber S., Albertsson P., Avilés F.F., et al. Task force for percutaneous coronary interventions of the European Society of Cardiology. Guidelines for percutaneous coronary interventions. Eur Heart J 26 (2005) 804-847
3. Svilaas T., Vlaar P.J., van der Horst I.C., et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 358 (2008) 557-567
4. De Luca G., Suryapranata H., Stone G.W., et al. Adjunctive mechanical devices to prevent distal embolization in patients undergoing mechanical revascularization for acute myocardial infarction: a meta-analysis of randomized trials. Am Heart J 153 (2007) 343-353
5. Burzotta F., Testa L., Giannico F., et al. Adjunctive devices in primary or rescue PCI: a meta-analysis of randomized trials. Int J Cardiol 123 (2008) 313-321
6. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction. JAMA 293 (2005) 1759-1765
7. Antoniucci D., Rodriguez A., Hempel A., et al. A randomized trial comparing primary infarct artery stenting with or without abciximab in acute myocadial infarction. J Am Coll Cardiol 42 (2003) 1879-1885
8. Karvouni E., Katritsis D.G., and Ioannidis J.P. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions. J Am Coll Cardiol 41 (2003) 26-32
9. Bellandi F., Maioli M., Gallopin M., Toso A., and Dabizzi R.P. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 62 (2004) 186-192
10. Wöhrle J., Grebe O.C., Nusser T., et al. Reduction of major adverse cardiac events with intracoronary compared with intravenous bolus application of abciximab in patients with acute myocardial infarction or unstable angina undergoing coronary angioplasty. Circulation 107 (2003) 1840-1843
11. Burzotta F., Romagnoli E., Trani C., and Crea F. Intracoronary administration of abciximab acutely increases flow through culprit vessels of patients with acute coronary syndromes undergoing percutaneous coronary intervention. Circulation 108 (2003) e138
12. Romagnoli E., Burzotta F., Trani C., et al. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol 105 (2005) 250-255
13. Andre P., Nannizzi-Alaimo L., Prasad S.K., and Phillips D.R. Platelet-derived CD40L: the switch-hitting player of cardiovascular disease. Circulation 106 (2002) 896-899
14. Henn V., Steinbach S., Buchner K., Presek P., and Kroczek R.A. The inflammatory action of CD40 ligand (CD154) expressed on activated human platelets is temporally limited by coexpressed CD40. Blood 98 (2001) 1047-1054
15. Nannizzi-Alaimo L., Alves V.L., and Phillips D.R. Inhibitory effects of glycoprotein IIb/IIIa antagonists and aspirin on the release of soluble CD40 ligand during platelet stimulation. Circulation 107 (2003) 1123-1128
16. Romagnoli E., Burzotta F., Trani C., et al. Rationale for intracoronary administration of abciximab. J Thromb Thrombolysis 23 (2007) 57-63
17. Furman M.I., Krueger L.A., Linden M.D., et al. GPIIb-IIIa antagonists reduce thromboinflammatory processes in patients with acute coronary syndromes undergoing percutaneous coronary intervention. J Thromb Haemostasis 3 (2005) 312-320
18. Dominguez-Rodriguez A., Abreu-Gonzalez P., Garcia-Gonzalez M.J., and Kaski J.C. Diurnal variation of soluble CD40 ligand in patients with acute coronary syndrome. Soluble CD40 ligand and diurnal variation. Thromb Res 123 (2009) 617-621
19. TIMI Study Group. The thrombolysis in myocardial infarction (TIMI) trial: phase 1 findings. N Engl J Med 312 (1985) 932-936
20. Gibson C.M., Murphy S.A., Morrow D.A., et al. Angiographic perfusion score: an angiographic variable that integrates both epicardial and tissue level perfusion before and after facilitated percutaneous coronary intervention in acute myocardial infarction. Am Heart J 148 (2004) 336-340
21. Schroeder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 110 (2004) e506-e510
22. Neumann F.J., Blasini R., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98 (1998) 2695-2701
23. Andre P., Prasad K.S., Denis C.V., et al. CD40L stabilizes arterial thrombi by a beta3 integrin-dependent mechanism. Nat Med 8 (2002) 247-252
24. Prasad K.S., Andre P., He M., et al. Soluble CD40 ligand induces [beta]3 integrin tyrosine phosphorylation and triggers platelet activation by outside-in signaling. Proc Natl Acad Sci USA 100 (2003) 12367-12371
25. Moser M., Bertram U., Peter K., Bode C., and Ruef J. Abiciximab, eptifibatide, and tirofiban exhibit dose-dependent potencies to dissolve platelet aggregates. J Cardiovas Pharmacol 4 (2003) 586-592
26. Collet J.P., Montalescot G., Lesty C., et al. Disaggregation of in vitro preformed platelet-rich clots by abciximab increases fibrin exposure and promotes fibrinolysis. Arterioscler Thromb Vasc Biol 21 (2001) 142-148
27. Marciniak Jr. S.J., Mascelli M.A., Furman M.I., et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemostasis 87 (2002) 1020-1025
28. Kintscher U., Kappert K., Schmidt G., et al. Effects of abciximab and tirofiban on vitronectin receptors in human endothelial and smooth muscle cells. Eur J Pharmacol 390 (2000) 75-87
29. Kiener P.A., Moran-Davis P., Rankin B.M., et al. Stimulation of CD40 with purified soluble gp39 induces proinflammatory responses in human monocytes. J Immunol 155 (1995) 4917-4925
30. Hollenbaugh D., Mischel-Petty N., Edwards C.P., et al. Expression of functional CD40 by vascular endothelial cells. J Exp Med 182 (1995) 33-40
31. Galache-Osuna J.G., Sánchez-Rubio J., Calvo I., et al. Does intracoronary abciximab improve outcome of percutaneous coronary interventions? A randomized controlled trial. Rev Esp Cardiol 59 (2006) 567-574
32. Kakkar A.K., Moustapha A., Hanley H.G., et al. Comparison of intracoronary vs. intravenous administration of abciximab in coronary stenting. Catheter Cardiovasc Interv 61 (2004) 31-34
33. Thiele H., Schindler K., Friedenberger J., et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: the randomized Leipzig immediate percutaneous coronary intervention abciximab IV versus IC in ST-elevation myocardial infarction trial. Circulation 118 (2008) 49-57
34. Férez Santander S.M., Márquez M.F., Peña Duque M.A., et al. Myocardial reperfusion injury. Rev Esp Cardiol 57 Suppl. 1 (2004) 9-21
35. Simon D.I., Xu H., Ortlepp S., Rogers C., and Rao N.K. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 17 (1997) 528-535
36. van't Hof A.W., Liem A., Suryapranata H., et al. Angiographic assessment of myocardial perfusion in patients treated with primary angioplasty for acute myocardial infarction: myocardial blush grade. Zwolle Myocardial Infarction Study Group. Circulation 97 (1998) 2302-2306